When Your Lungs Decide to Go Full Thanos: A Rare Cancer Meets Its Match

Pulmonary sarcomatoid carcinoma and a Marvel villain have more in common than you'd think. Both are rare, both are terrifyingly aggressive, and both seem designed to make heroes' lives miserable. But unlike the Avengers, oncologists fighting PSC have been working without a decent playbook—until now.

The Villain Nobody Talks About

PSC is the Keyser Söze of lung cancers—rare enough that most people have never heard of it, but absolutely devastating when it shows up. Making up only about 0.1-0.4% of all lung cancers, this tumor type combines the worst features of regular lung cancer with sarcoma-like elements, creating something that spreads faster and responds worse to standard treatments than your typical non-small cell lung cancer [1].

Think of it like this: if regular lung cancer is a problematic houseguest who overstays their welcome, PSC is that houseguest who also invites friends, raids your fridge, and sets small fires in the bathroom. Median survival for advanced cases has historically been measured in months, not years, and chemotherapy alone tends to work about as well as a screen door on a submarine [2].

Enter the Dynamic Duo

Researchers in China decided to try something different: combining tislelizumab (an immune checkpoint inhibitor) with anlotinib (an anti-angiogenic drug). In Netflix terms, tislelizumab is like removing the "skip intro" button that cancer cells use to avoid immune detection, while anlotinib cuts off the tumor's DoorDash supply line—its blood vessel network [3].

The trial enrolled 29 patients with advanced PSC who hadn't received prior treatment. The median age was 71, proving once again that cancer has zero respect for retirement plans.

The Results (Spoiler Alert: Actually Good)

Here's where it gets interesting. Over half the patients—55.17% to be precise—showed objective responses to treatment. Two patients achieved complete responses, meaning their tumors pulled a disappearing act worthy of a prestige film's third act. Another 14 had partial responses. The disease control rate hit a remarkable 96.55% [4].

Median progression-free survival came in at 9.4 months, with overall survival reaching 14.37 months. For a cancer type where "aggressive" is an understatement and historical outcomes have been genuinely grim, these numbers represent real progress.

The Side Effect Situation

No cancer treatment comes without a cost, and this combination was no exception. The most common issues were hyperuricemia (elevated uric acid) and maculopapular rash—annoying, certainly, but manageable. About 28% of patients experienced grade 3-4 adverse events, the more serious stuff that requires intervention. Critically, nobody died from treatment-related causes [4].

For context, that's a safety profile that oncologists can actually work with, especially when the alternative is a disease that's essentially playing on Nightmare difficulty.

Why This Matters Beyond the Numbers

PSC has been the awkward stepchild of lung cancer research. It's too rare for big pharma to prioritize, too aggressive for patients to wait around for better options, and too different from standard NSCLC for existing treatments to translate well [5]. This trial represents one of the first prospective studies specifically designed for this patient population.

The combination approach makes biological sense too. PSC tumors tend to have high PD-L1 expression (the immune system's "do not attack" sign) and are highly vascularized (lots of blood vessels feeding the tumor). Targeting both pathways simultaneously is like attacking a fortress while also cutting its supply lines—basic strategy that somehow took us this long to try in this specific cancer [3].

The Fine Print

This was a single-arm phase II trial with 29 patients at one center. That's not nothing, but it's also not the final word. Larger, randomized trials will need to confirm these findings. The patients also had to lack EGFR or ALK mutations—genetic changes that have their own targeted therapies—so this approach isn't for everyone.

Still, for a disease that's been largely ignored by the treatment algorithm gods, having something that works more than half the time is genuinely meaningful progress.

The Bottom Line

PSC remains a formidable opponent, but this immunotherapy-plus-anti-angiogenic combination gives patients and doctors a legitimate first-line option where few existed before. It's not a cure, and it's not perfect, but it's a real step forward for a cancer type that desperately needed one.

Sometimes the best sequels are the ones nobody expected.

References:

1. Travis WD, et al. The 2015 World Health Organization Classification of Lung Tumors. J Thorac Oncol. 2015;10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630

2. Vieira T, et al. Sarcomatoid lung cancer: a study of 139 cases. Clin Lung Cancer. 2016;17(5):391-397. DOI: 10.1016/j.cllc.2016.01.004

3. Shen G, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. DOI: 10.1186/s13045-018-0664-7

4. Zeng Z, et al. The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial. Clin Cancer Res. 2025. DOI: 10.1158/1078-0432.CCR-25-4770

5. Yendamuri S, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery. 2012;152(3):397-402. DOI: 10.1016/j.surg.2012.05.007

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.